Skip to content

Author

Katerina Saltiki

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

How to manage autoimmune hyperthyroidism (Graves’ disease): from differential diagnosis to emerging immunological therapies

Graves’ disease is an autoimmune disorder and represents the most prevalent cause of hyperthyroidism. Its pathogenesis involves a complex interplay of immunological mechanisms, with a central role attributed to stimulating autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR) expressed on thyr...

O. Karapanou, Katerina Saltiki, G. Markantes et al. · 1 citation
Review Open access Aug 2026

How to manage thyroid eye disease: recent advances – a narrative review

Thyroid eye disease (TED) is a complex autoimmune disorder and the most common extrathyroidal manifestation of Graves’ disease, characterized by orbital inflammation, tissue remodelling, and varying degrees of functional and cosmetic impairment. Although often mild, moderate-to-severe and sight-threatening forms can si...

G. Markantes, G. Effraimidis, O. Karapanou et al. · 1 citation
Review Open access Aug 2026

How to manage medullary thyroid carcinoma: current treatment strategies

Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy, representing approximately 2–5% of all thyroid cancers. It develops from the parafollicular C cells of the thyroid gland. Calcitonin, produced by parafollicular C cells, is a highly reliable biomarker for both diagnosis and disease monitoring. MTC commonly...

Katerina Saltiki, O. Karapanou, M. Michalaki et al. · 0 citations
Review Open access Sep 2026

Calcitonin-negative 'MTC-like' thyroid paraganglioma revealing an SDHD-related hereditary paraganglioma syndrome: functional confirmation of a non-canonical splice-site variant.

INTRODUCTION Primary thyroid paraganglioma (TPGL) is a rare mimic of medullary thyroid carcinoma (MTC). We report an SDHD-related TPGL caused by a non-canonical splice-region variant. CASE PRESENTATION A 36-year-old woman underwent thyroidectomy for a 20 mm EU-TIRADS 4 Bethesda III thyroid nodule with normal serum ca...

G. Effraimidis, V. Trachana, Evmorfia Tzagkaraki et al. · 0 citations
Open access Aug 2026

P461 - LBA_ECE_1060 - Functional characterization of a non-canonical SDHD splice-site variant (c.314+4A > G) in a family with thyroid and carotid paragangliomas

Direct RNA-level evidence is provided that the intronic SDHD c.314+4A > G variant causes aberrant splicing and supports reclassification from VUS to likely pathogenic under ACMG/AMP criteria and underscore the value of RNA-based assays in interpreting non-canonical splice-site changes.

G. Effraimidis, V. Trachana, Evmorfia Tzagkaraki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.